Aristides Capital LLC acquired a new stake in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,400 shares of the medical equipment provider’s stock, valued at approximately $178,000.
Other institutional investors also recently modified their holdings of the company. Norges Bank bought a new position in NovoCure during the 4th quarter valued at approximately $14,543,000. Federated Hermes Inc. raised its holdings in shares of NovoCure by 807.8% during the fourth quarter. Federated Hermes Inc. now owns 616,792 shares of the medical equipment provider’s stock valued at $9,209,000 after acquiring an additional 548,852 shares in the last quarter. Invenomic Capital Management LP purchased a new stake in NovoCure in the fourth quarter worth $6,479,000. C WorldWide Group Holding A S boosted its holdings in NovoCure by 135.3% in the fourth quarter. C WorldWide Group Holding A S now owns 521,784 shares of the medical equipment provider’s stock valued at $7,790,000 after acquiring an additional 300,000 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in NovoCure by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 10,023,981 shares of the medical equipment provider’s stock valued at $156,675,000 after purchasing an additional 264,883 shares during the period. 84.61% of the stock is currently owned by hedge funds and other institutional investors.
NovoCure Stock Up 2.0 %
NovoCure stock traded up $0.37 during mid-day trading on Friday, hitting $19.02. The company had a trading volume of 1,236,980 shares, compared to its average volume of 1,881,869. The stock’s 50 day moving average price is $19.84 and its two-hundred day moving average price is $16.56. The company has a current ratio of 6.26, a quick ratio of 5.99 and a debt-to-equity ratio of 1.59. The company has a market capitalization of $2.05 billion, a PE ratio of -10.51 and a beta of 0.70. NovoCure Limited has a 12 month low of $10.87 and a 12 month high of $41.51.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on the stock. HC Wainwright boosted their price target on shares of NovoCure from $22.00 to $24.00 and gave the company a “neutral” rating in a research report on Friday. Wells Fargo & Company decreased their target price on NovoCure from $42.00 to $40.00 and set an “overweight” rating for the company in a research report on Friday. Piper Sandler restated an “overweight” rating and issued a $28.00 target price (up previously from $25.00) on shares of NovoCure in a research note on Wednesday, April 10th. Evercore ISI upped their price target on NovoCure from $14.50 to $20.00 and gave the stock an “in-line” rating in a research note on Tuesday, July 2nd. Finally, Wedbush reissued an “outperform” rating and set a $24.00 price objective on shares of NovoCure in a research report on Thursday. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, NovoCure presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.88.
View Our Latest Stock Analysis on NovoCure
NovoCure Profile
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.
See Also
- Five stocks we like better than NovoCure
- Investing in the High PE Growth Stocks
- Is Crypto Cool Again? What Stocks You Should Be Watching
- Canada Bond Market Holiday: How to Invest and Trade
- Why Call Options Volume for These 2 Stocks Spiked Together
- Russell 2000 Index, How Investors Use it For Profitable Trading
- MarketBeat Week in Review – 7/22 – 7/26
Want to see what other hedge funds are holding NVCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NovoCure Limited (NASDAQ:NVCR – Free Report).
Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.